Global Presbyopia Treatment Market Grows Steadily at a CAGR of 5.5%

Introduction

Presbyopia treatment encompasses a broad range of ophthalmic and surgical interventions designed to restore near vision, a condition that naturally occurs with aging. The primary treatment modalities include corrective eyewear such as reading glasses, bifocals, and progressive lenses, as well as contact lenses, which can be multifocal or monovision to accommodate different visual needs.

Beyond traditional optical solutions, advanced treatment options such as intraocular lenses (IOLs), corneal inlays, laser procedures, and pharmacological treatments (like presbyopia-correcting eye drops) are gaining popularity. With ongoing innovations in vision correction technology, patients now have access to a variety of personalized solutions, enhancing both convenience and effectiveness in managing presbyopia.

Market Dynamics

The increasing prevalence of distance vision impairment drives the global market

The increasing prevalence of distance vision impairment is a significant factor fueling the expansion of the presbyopia treatment market. As more individuals struggle with deteriorating vision, the demand for advanced treatment options continues to rise.

• According to the World Health Organization (WHO), as of August 2023, at least 2.2 billion people worldwide suffer from vision impairment, with 1 billion cases being either preventable or treatable.

This highlights the critical need for innovative presbyopia treatments, including surgical procedures, non-surgical interventions, and pharmacological solutions, further propelling market growth.

Advancements in pharmacological treatments for presbyopia create tremendous opportunities

Advancements in pharmacological treatments are revolutionizing the presbyopia market by providing non-invasive solutions that eliminate the need for glasses or surgery. Eye drops, in particular, have emerged as a promising alternative to traditional methods.

• For example, the U.S. Food and Drug Administration (FDA) approved VUITY, the first presbyopia treatment eye drop formulated with 1.25% pilocarpine HCl, which enhances near vision through a pinhole effect.

Such innovations are reshaping the market landscape, offering new opportunities for patients seeking convenient and effective presbyopia treatment, further driving market expansion.

Regional Analysis

North America holds a dominant position in the global presbyopia treatment market, driven by a high incidence of presbyopia, advanced healthcare infrastructure, and rapid adoption of innovative treatments. The region's strong market growth is supported by the high penetration of novel interventions such as pharmaceutical treatments and advanced surgical options. Moreover, rising awareness, favorable reimbursement policies, and increasing demand for premium intraocular lenses (IOLs) are all key factors propelling market expansion.

Key Highlights

• The global presbyopia treatment market size was valued at USD 10.17 billion in 2024 and is projected to grow from USD 10.91 billion in 2025 to reach USD 16.77 billion by 2033, exhibiting a CAGR of 5.5% during the forecast period (2025-2033).
• Based on treatment, the global presbyopia treatment market is segmented into surgical treatment, corrective lenses, and pharmacological treatment. The corrective lenses segment is the largest revenue contributor to the market.
• Based on end-users, the global presbyopia treatment market is segmented into hospitals, ophthalmology clinics, ambulatory surgical centers (ASCS), and others. The hospital segment is the largest revenue contributor to the market.
• North America is the highest shareholder in the global market.

Competitive Players

1. Ziemer Ophthalmic Systems AG
2. NIDEK CO. LTD.
3. Johnson & Johnson Vision
4. Essilor Ltd.
5. Bausch & Lomb
6. Haag-Streit
7. Allergan (AbbVie Inc.)
8. STAAR Surgical
9. LENZ Therapeutics Inc

Recent Developments

• In October 2024, LENZ Therapeutics, Inc. stated that its New Drug Application (NDA) for LNZ100 has been accepted by the U.S. Food and Drug Administration (FDA) LNZ100: First in class aceclidine eyedrop for presbyopia-induced near vision loss.

Segmentation

1. By Treatment
   1. Surgical Treatment
      1. Refractive Surgery
         1. Laser-assisted in situ keratomileusis (LASIK)
         2. PRK (Photorefractive Keratectomy)
         3. Others
      2. Corneal Inlays
      3. Scleral Implants
      4. Lens Replacement Surgery
         1. Monofocal IOLs
         2. Multifocal IOLs
         3. Accommodative IOLs
   2. Corrective Lenses
      1. Eyeglasses
         1. Bifocal
         2. Trifocal
         3. Progressive Lenses
         4. Others
      2. Contact Lenses
         1. Bifocal Contact Lenses
         2. Multifocal Contact Lenses
         3. Modified monovision
   3. Pharmacological Treatment
2. By End-User
   1. Hospitals
   2. Ophthalmology Clinics
   3. Ambulatory Surgical Centers (ASCs)
   4. Others
3. By Regions
   1. North America
   2. Europe
   3. Asia-Pacific
   4. Central & South America
   5. The Middle East and Africa